Engflag

Cefurox 500

Quick links to important sections

Cefurox 500

Cefurox 500_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefurox 500

Cefurox 500 is a prescription-only medicine containing the active compound Cefuroxime, classified as a semisynthetic beta-lactam antibiotic. This drug is specifically designated as a systemic antimicrobial agent, meaning its primary function is to circulate throughout the body to treat and eliminate susceptible bacterial infections.

Property Description
Active Ingredient Cefuroxime (as Cefuroxime axetil)
Form Oral film-coated tablet (500 mg strength)
Pharmacological Class Second-generation cephalosporin
Classification Prescription-only Medicine (Rx)
Origin Semisynthetic

What Type of Medicine is Cefurox 500 and How is it Classified?

Cefurox 500 contains Cefuroxime, chemically categorized as a second-generation cephalosporin antibiotic, a subclass within the larger family of beta-lactam antibiotics. This medication is clinically recognized for its broad-spectrum capability against a range of bacteria, including Gram-positive and Gram-negative organisms, making it an established choice for combating various infections.

Cefuroxime Composition: What Active Ingredient is in Cefurox 500?

The core component of the Cefurox 500 oral tablet is Cefuroxime, delivered as its precursor, Cefuroxime axetil. This compound functions as a prodrug, which is intentionally designed for better absorption after oral administration before being rapidly converted into the active Cefuroxime within the body. The oral formulation is a film-coated tablet, a feature often used to mask the strong, bitter taste associated with the raw active ingredient, thereby improving patient acceptance.

What is the General Purpose of Taking Cefuroxime?

The general purpose of Cefuroxime is to provide potent antimicrobial therapy necessary for the resolution of systemic bacterial infections. Its effectiveness is based on a bactericidal action that works by binding to essential target proteins in the pathogen, thereby inhibiting bacterial cell wall synthesis. This disruption is critical for eliminating the bacterial presence, which is the general therapeutic goal of the medication.

Regulatory References

  1. Cefuroxime - StatPearls - NCBI Bookshelf
  2. Cefuroxime Axetil Tablets, USP - DailyMed

What side effects are possible with Cefurox 500?

Possible Side Effects and Safety Information

The safety profile of Cefurox 500 (Cefuroxime) is organized by official regulatory bodies based on the frequency and the affected System-Organ Class (SOC). Adverse reactions are classified from Common (occurring in 1 to 10 out of 100 people) to Uncommon, Rare, Very Rare, and Frequency Not Known.

Common and SOC-Classified Adverse Reactions

The most frequently documented effects are categorized as Common and involve the Gastrointestinal disorders and Nervous system disorders SOCs. These include conditions such as diarrhea, nausea, headache, and dizziness. Other common effects include candidiasis and changes in blood cell counts, such as eosinophilia. Uncommon effects often involve the Blood and lymphatic system (e.g., leukopenia) and Skin and subcutaneous tissue disorders (e.g., rash).

Serious Adverse Reactions and Safety Constraints

The regulatory label documents the potential for Rare but serious adverse reactions, which require formal attention. These include severe, immediate hypersensitivity reactions like Anaphylaxis and severe skin conditions such as Stevens-Johnson syndrome (SJS). Clostridioides difficile-associated diarrhea (CDAD) is also a documented serious gastrointestinal risk, which may occur during or up to two months after treatment completion.

Cefuroxime is formally contraindicated in individuals with a known history of hypersensitivity to cephalosporins or any severe allergy to other beta-lactam antibiotics. Furthermore, caution is noted for patients with renal impairment. The medication may also cause a false-positive result in specific copper-reduction laboratory tests used for glucose monitoring.

Overdose and Emergency Response

Cefuroxime overdose is primarily documented in regulatory sources for its potential to affect the Central Nervous System (CNS). Officially recognized manifestations of overdose may include signs of cerebral irritation, which can lead to convulsions or generalized seizures. Further severe outcomes cited in the regulatory context include the potential for neurological sequelae, such as encephalopathy and coma. In situations of high exposure, such as those that may occur if the dose is not appropriately reduced in individuals with renal impairment, this toxicity risk is elevated due to the drug’s slower clearance.

Immediate emergency medical attention is required in all suspected cases of overdose. Regulatory guidance explicitly states that emergency services must be contacted immediately if an individual has collapsed, experiences severe difficulty breathing, has had a seizure, or is unable to be awakened.

Management of Cefuroxime overdose is defined as symptomatic and supportive treatment. The official label states that no specific antidote is documented for Cefuroxime. The level of Cefuroxime in the blood can be successfully reduced using recognized procedural measures, specifically haemodialysis and peritoneal dialysis.

Therapeutic Uses of Cefurox 500

Cefuroxime is a medication used in situations involving certain distressing symptoms associated with susceptible bacterial infections. The medication is commonly used across conditions presenting with acute episodes, including infections of the respiratory tract (such as sinusitis, tonsillitis, and bronchitis), uncomplicated urinary tract infections (UTIs), skin conditions, and early Lyme disease. It helps address symptom clusters related to physical discomfort.

Key Focus: Management of Acute Symptoms

Cefuroxime is relevant when supportive symptom management is appropriate and supports the patient during difficult episodes by easing distress. This approach assists with maintaining functional stability and comfort.

“The medication is applied when symptomatic management is necessary to help ease symptom clusters, and supports general well-being during symptomatic phases.”

Regulatory References

  1. Official FDA-Approved Label for Cefuroxime Axetil (via NIH DailyMed)

Eligibility and Restrictions for Use

Who Can and Cannot Use Cefurox 500?

Cefurox 500 (Cefuroxime axetil) eligibility is strictly defined by regulatory documents based on patient history, age, and physiological status.

Contraindications (Who Must Not Use)

The medicine is contraindicated in patients with known hypersensitivity to Cefuroxime axetil or any other cephalosporin antibiotic. Furthermore, use is prohibited in patients with a history of severe hypersensitivity reaction to any other beta-lactam antibacterial drug, such as penicillins or carbapenems. This absolute non-eligibility is defined by the drug's beta-lactam class.

Eligibility and Restrictions

Population Group Eligibility Status (Regulatory Label)
Adults and Adolescents Established for use in adults and pediatric patients aged 13 years and older (tablet formulation).
Infants (< 3 Months) Use not established; safety and effectiveness data are insufficient for this age group.
Renal Impairment Conditional use in patients with markedly impaired renal function; dose adjustment is required.
Pregnancy/Lactation Restricted use; prescribed only after a benefit/risk assessment is determined to be favorable.
Gastrointestinal Disorders Use with caution is advised for patients with a history of colitis or severe intestinal tract disorders due to absorption concerns.

What should I know about interactions with other medicines?

Cefurox 500 Interactions with other medicines and products

This section summarizes officially documented interactions based on government regulatory prescribing information for Cefuroxime axetil.

Interacting Medicines and Products

Category Interacting Entity Official Regulatory Statement
Exposure Modifier Probenecid Co-administration is not recommended as it increases the systemic exposure of Cefuroxime by inhibiting renal tubular secretion, thereby decreasing clearance.
Gastric Acidity Reducers H2-antagonists & PPIs Co-administration should be avoided as these agents reduce gastric acidity and cause lower bioavailability of Cefuroxime axetil.
Contraceptives Oral Contraceptives May lower the efficacy of oral contraceptives due to a potential effect on gut flora, which can reduce the reabsorption of estrogen compounds.
Food Effect Food (Postprandial state) Administration after food increases the absolute bioavailability of the tablet formulation.

Interaction-Related Constraints and Procedures

  • Short-acting Antacids: Short-acting antacids (e.g., those containing aluminum or magnesium hydroxide) must be administered at least 1 hour before or 2 hours after Cefuroxime axetil to mitigate reduced absorption.
  • Laboratory Tests: Cefuroxime may cause a false-positive reaction for glucose in the urine with copper reduction tests and a false-negative result in the ferricyanide test for blood/plasma glucose. Enzyme-based tests are recommended for glucose determination.

Mechanism of Action

Cefurox 500 contains Cefuroxime, a beta-lactam antibiotic that functions by directly disrupting the core structural integrity of susceptible bacteria, resulting in a bactericidal effect.

Cefuroxime targets and irreversibly inhibits a class of bacterial enzymes known as Penicillin-binding proteins (PBPs), particularly PBP 3. The drug binds covalently to these transpeptidases, blocking the critical process of peptidoglycan cross-linking necessary for cell wall formation.

This failure of the cell wall's structural integrity leads to a fatal osmotic imbalance, which subsequently activates the bacteria's own latent autolytic enzymes. This cascade results in the rapid and widespread cell lysis (rupture), producing a direct bactericidal effect.

However, the mechanism is constrained when certain bacteria produce beta-lactamase enzymes, which enzymatically destroy the Cefuroxime molecule before it can reach its PBP target. The mechanism also exhibits reduced efficacy against strains that possess altered PBP structures with a reduced binding affinity.

Dosage and Administration Information

Cefurox 500 contains Cefuroxime axetil and is officially administered via the oral route using the film-coated tablet. The standard regimen for most conditions requires administration twice daily, meaning a dose must be taken every 12 hours.

Standard Dosing and Duration

The dosage of the tablet form varies by the specific condition being addressed, ranging from 250 mg to 500 mg per dose. The duration of treatment is fixed by the official label, typically ranging from 7 to 10 days for common infections. For example, the treatment course for early Lyme disease is extended to 20 days, while uncomplicated gonorrhea requires a 1,000 mg single dose.

Administration Conditions and Adjustments

To ensure optimum drug absorption, the tablets are to be taken after consuming food. The film-coated tablet must be swallowed whole and must not be crushed, as crushing the tablet releases a strong, persistent bitter taste. The tablet and the oral suspension are officially not substitutable on a milligram-per-milligram basis.

For patients with markedly impaired renal function (Creatinine Clearance <30 mL/min), the standard dose frequency is officially reduced to every 24 or 48 hours to compensate for the drug’s slower excretion. No dose adjustment is specified for older adults based on age alone. If a dose is missed, it should be taken as soon as remembered, but never doubled to compensate for a skipped dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Cefurox 500

Evidence for Common Infections

The evidence base for Cefuroxime axetil in treating common acute infections, such as those in the respiratory passages (sinusitis, pharyngitis) and uncomplicated urinary tract infections (UTIs), is primarily composed of Randomized Controlled Trials (RCTs). These studies evaluated adults, adolescents, and children. Researchers monitored two main areas: outcomes related to the resolution of symptoms (physical discomfort) and outcomes related to bacteriological eradication. Studies monitored patterns observed in how symptoms evolved over short post-treatment periods. Comparative trials explored differences between Cefuroxime axetil and other established oral regimens. Data for these conditions largely relates to uncomplicated cases.

Research for Early Lyme Disease

Cefuroxime axetil was evaluated in research for the early stage of Lyme disease (Erythema Migrans). These trials included an extended-duration follow-up, with some monitoring patients for up to one year to track long-term clinical status. Evidence from oral formulations, however, is limited regarding the assessment of later-stage manifestations of Lyme disease.

Evidence Gaps and Research Uncertainty

The clinical trials generally included patients with uncomplicated, mild-to-moderate disease. As a result, research data for severe, complicated, or deep-seated infections is limited. Evidence quality varies across studies, and long-term effects are not fully established for all possible patient scenarios. While pediatric and older adult populations were included, data for patients with complex pre-existing conditions, such as severe kidney issues, remains insufficient.

Key Studies & References

  1. CEFUROXIME AXETIL tablet - DailyMed - NIH (US Regulatory Information)
  2. Cefuroxime - StatPearls - NCBI Bookshelf (General Evidence Review)

How should Cefurox 500 be stored and disposed of?

How to Store and Dispose of Cefurox 500?

The storage and disposal of Cefurox 500 (Cefuroxime axetil 500 mg tablets) must strictly adhere to regulatory requirements to maintain product quality and safety.

Official Storage Requirements

Condition Requirement
Temperature Store at a temperature not exceeding 30°C.
Container Keep in the original container to protect from moisture and light.
Child Safety Keep out of the sight and reach of children (mandatory for all prescription medicines).

Pharmaceutical Waste Disposal

Official instructions for unused or expired tablets state that they must not be flushed down the toilet.

To dispose of the product, tablets should be mixed with an undesirable substance (such as dirt or coffee grounds), placed in a sealed container, and then discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cefurox 500 found in:

A-Z Index: